Twist Bioscience Corp.

Twist Bioscience Corp. achieved a new 52-week high of USD 104.45, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a significant stock price increase over the past year, outperforming the S&P 500, despite being loss-making and lacking a dividend yield.

Twist Bioscience Corp. has achieved a new 52-week high, reflecting its strong performance with a significant increase over the past year. With a market capitalization of USD 2,730 million, the company operates in a competitive biotechnology sector, though it currently faces challenges with negative return on equity and a premium valuation.

Twist Bioscience Corp. has achieved a new 52-week high, reflecting a strong performance with a significant increase over the past year. With a market capitalization of USD 2,730 million, the company operates in a competitive biotechnology sector, despite currently facing losses and a premium valuation.

Twist Bioscience Corp. achieved a new 52-week high of USD 82.87, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 61.55% growth over the past year, significantly outpacing the S&P 500, despite being loss-making and lacking a dividend yield.

Twist Bioscience Corp. has seen a notable increase in its stock price, reaching an intraday high of USD 74.28. The company reported record net sales of USD 110.72 million last quarter, despite a net loss. Its strong performance metrics highlight significant investor confidence and resilience in the biotechnology sector.

Twist Bioscience Corp. has reached a new 52-week high, reflecting a substantial increase over the past year and outperforming the S&P 500. The company, with a market capitalization of USD 2,760 million, remains unprofitable and has a high price-to-book ratio, indicating a premium valuation.

Twist Bioscience Corp. has seen notable stock performance, with significant gains over the past week and month, and an impressive one-year increase. Despite facing financial challenges, the company maintains strong institutional support, reflecting confidence from investors and solidifying its position in the biotechnology sector.

Twist Bioscience Corp. has achieved a new 52-week high, showcasing its strong performance in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 2.76 billion, the company has seen a significant increase over the past year, despite being loss-making and focusing on growth and reinvestment.

Twist Bioscience Corp. has achieved a new 52-week high of USD 66.84, reflecting a strong performance with a 28.31% increase over the past year. The company, with a market capitalization of USD 2,760 million, remains unprofitable and has a price-to-book ratio of 6.05.

Twist Bioscience Corp. has seen significant stock price growth, outperforming the S&P 500 over the past week and year. Despite challenges such as negative operating cash flow and net profit, the company enjoys strong institutional backing, indicating investor confidence in its potential within the biotechnology sector.

Twist Bioscience Corp. has seen a notable increase in stock performance, significantly outperforming the S&P 500 over the past week. Despite recent monthly declines, the company has demonstrated strong year-to-date and three-year growth. High institutional holdings indicate investor confidence, even amid challenging financial metrics.

Twist Bioscience Corp. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. Despite operating at a loss and facing challenges in financial metrics, the company's stock has significantly increased from its previous low, indicating resilience and potential growth in the market.

Twist Bioscience Corp. has achieved a new 52-week high, reflecting a strong performance over the past year. Despite being a loss-making entity, the company maintains a significant market capitalization and operates in a competitive biotechnology sector, highlighting its ongoing innovation and growth potential.

Twist Bioscience Corp. achieved a new 52-week high of USD 61.61 on April 17, 2026, reflecting its position in the Pharmaceuticals & Biotechnology sector. Despite a 19.6% performance increase over the past year, the company operates at a loss and has a negative return on equity.

Twist Bioscience Corp. has achieved a new 52-week high of USD 59.90, significantly up from its low of USD 23.50. Despite a 15.22% performance increase over the past year, the company remains unprofitable, with a market capitalization of USD 2,760 million and a negative return on equity.

Twist Bioscience Corp. has recently experienced a stock price adjustment, reflecting its current market dynamics. The company has shown resilience with a year-to-date return of 40.38%, significantly outperforming the S&P 500. However, its five-year performance indicates challenges, with a decline compared to the broader market.

Twist Bioscience Corp. experienced a notable gain today, despite facing a decline over the past month. The company reported a 16.89% increase in net sales, yet its annual return remains significantly lower than the S&P 500. High institutional ownership indicates strong investor interest, though financial metrics reveal ongoing challenges.

Twist Bioscience Corp. faced a notable stock decline, reaching an intraday low amid a challenging trading session. Despite a year-to-date performance exceeding the S&P 500, the company has struggled over the past year. Financial metrics reveal growth in net sales, but significant operating losses persist.

Twist Bioscience Corp. has faced significant stock declines recently, with a notable drop over the past month. Despite some technical indicators suggesting a mildly bullish trend, the company is grappling with financial challenges, including a negative return on equity and a market capitalization of around USD 2,760 million.